Tufts Medical Center

Running trials

• Not yet recruiting

  Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity

  NCT07911046· Source

• Recruiting

  PrEcision Pacing in HFpEF: the PEP-HFpEF Trial

  NCT07864558· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· Source

• Recruiting

  Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

  NCT07718854· Phase 2· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Not yet recruiting

  Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

  NCT06016517· Source

• Not yet recruiting

  Promoting Physical Activity Among Young Children With Autism

  NCT07747129· Source

• Recruiting

  Vitamin D and Type 2 Diabetes - Treat-To-Target

  NCT07448974· Phase 3· Source

• Recruiting

  HCMR Re-Imaging Study

  NCT07054073· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Source

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Source

• Recruiting

  Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

  NCT07232030· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Source

• Recruiting

  The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

  NCT07143019· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Source

• Recruiting

  Pulmonary Embolism and Right-to-Left Shunts

  NCT07519876· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Source

• Enrolling by invitation

  A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

  NCT07156578· Phase 2· Source

• Recruiting

  Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  NCT06769126· Phase 2· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· Source

• Recruiting

  OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

  NCT06939751· Source

• Recruiting

  Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

  NCT07172464· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· Source

• Recruiting

  Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  NCT06577441· Phase 2· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Source

• Recruiting

  Alleviant ALLAY-HFrEF Study

  NCT06812533· Source

• Recruiting

  Myo-inositol During Pregnancy to Prevent Gestational Diabetes

  NCT06575868· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Family-Based Weight Wellness Treatment Through Food is Medicine and Group Medical Visits in Pediatric and Adult Primary Care

  NCT07717658· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· Source

• Active, not recruiting

  Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

  NCT06747572· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Source

• Recruiting

  Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

  NCT06569147· Phase 1/2· Source

• Active, not recruiting

  Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  NCT06310031· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure12 recruiting
• Acute myeloid leukemia7 recruiting
• Childhood cancers5 recruiting
• Multiple myeloma5 recruiting
• Ovarian cancer5 recruiting
• Stroke5 recruiting
• Amyloidosis4 recruiting
• High blood pressure4 recruiting
• Obesity4 recruiting
• Pulmonary arterial hypertension4 recruiting
• Bladder cancer3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Head and neck cancer3 recruiting
• Lung cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Cervical cancer2 recruiting
• Colorectal cancer2 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Kidney cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Sjögren's disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Alzheimer disease1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Schizophrenia1 recruiting
• Thyroid cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Source

• Withdrawn

  Using WHOOP Fitness Band to Measure Heart Health Variability Before and After Surgery

  NCT07097168· Source

• Terminated

  Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

  NCT06543446· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Source

• Completed

  A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

  NCT06046443· Phase 2· Source

• Withdrawn

  Study of ADI CardioPulmonary Management (CPM) System

  NCT06024369· Source

• Completed

  Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

  NCT05763667· Phase 3· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Source

• Completed

  Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

  NCT06150924· Phase 2· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Source

• Completed

  Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

  NCT05834738· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Source

• Completed

  A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05521191· Phase 1· Source

• Completed

  Development and Evaluation of "Period Kits" for Adolescents With Intellectual and Developmental Disabilities

  NCT05497167· Source

• Completed

  A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes

  NCT05280496· Phase 3· Source

• Completed

  Apple Watch Heart Failure Study

  NCT04510779· Source

• Terminated

  Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

  NCT05251727· Phase 1· Source

• Completed

  Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

  NCT03941860· Phase 3· Source

• Terminated

  A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

  NCT04856176· Phase 2· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Food As Medicine for Heart Failure

  NCT04847973· Source

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Phase 2· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· Source

• Completed

  The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

  NCT04325035· Phase 2· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Source

• Completed

  SURPASS Impella 5.5 Study

  NCT05100836· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Phase 3· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· Source

• Terminated

  Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

  NCT04217746· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· Source

Trial sites

• Tufts Medical Center226 trials
• Tufts Medical Center - 800 Washington St - PPDS1 trial
• Tufts Medical Center (Data Collection Only)1 trial
• Tufts Medical Center, Division of Hematology and Oncology1 trial
• Tufts Medical Center /ID# 1435811 trial
• Tufts Medical Center /ID# 1536721 trial
• Tufts Medical Center /ID# 1651441 trial
• Tufts Medical Center /ID# 2005701 trial
• Tufts Medical Center /ID# 2150531 trial
• Tufts Medical Center /ID# 2159251 trial
• Tufts Medical Center /ID# 2161101 trial
• Tufts Medical Center /ID# 2460741 trial
• Tufts Medical Center /ID# 2695471 trial
• Tufts Medical Center - Neurology2 trials
• Tufts Medical Center - PPDS (Site 1012)2 trials
• Tufts Medical Center - Rheumatology Research Office - PPDS1 trial
• Tufts Medical Center (Site 0024)1 trial
• Tufts Medical Center (Site 1012)1 trial
• Tufts Medical Center (Site 3408)1 trial
• Tufts Medical Center - Site #3491 trial
• Tufts Medical Center (Site 6052)1 trial
• Tufts Medical Center- Site Number : 84000031 trial
• Tufts Medical Center- Site Number : 84000724 trials
• Tufts Medical Center-Site Number: 84001262 trials
• Tufts Medical Center Site Number : 84012011 trial
• Tufts New England Medical Center1 trial
• Tufts University School of Medicine (Tusm) - Tufts Medical Center (Tmc) (Tufts-New England Medical Center)1 trial
• Tufts University/Tufts Medical Center1 trial
• Tufts Medical Center1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure102 works · 27 trials
• Amyloidosis16 works · 8 trials
• Pulmonary arterial hypertension15 works · 12 trials
• Polycystic kidney disease6 works · 4 trials